1-12 of 12
Sarah P. Blagden
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract CT156: Phase 1 dose-optimization study evaluating the safety of ginisortamab (UCB6114), an anti-gremlin-1 monoclonal antibody (mAb) with first-in-class potential, as monotherapy in advanced solid tumors

Free
Debashis Sarker, Toros A. Dincman, Ruth Plummer, Udai Banerji, Natalie Cook, Heinz-Josef Lenz, Mark White, Elodie Garric, Paul Jones, Joanne Mann, Ivan Matthews, Abdul (Moe) Munith, Sarah P. Blagden
Journal: Cancer Research
Cancer Res (2025) 85 (8_Supplement_2): CT156.
https://doi.org/10.1158/1538-7445.AM2025-CT156
Published: 25 April 2025
View articletitled, Abstract CT156: Phase 1 dose-optimization study evaluating the safety of ginisortamab (UCB6114), an anti-gremlin-1 monoclonal antibody (mAb) with first-in-class potential, as monotherapy in advanced solid tumors
Journal Articles

Abstract 5650: RNA regulatory disruption by 3’-dATP: A novel approach to inhibit ribosome biogenesis in cancer

Free
Mustafa Elshani, Ying Zhang, In Hwa Um, Ruth Plummer, Sarah P. Blagden, Stefan N. Symeonides, Natalie Cook, T.R. Jeffry Evans, Alison L. Dickson, David J. Harrison
Journal: Cancer Research
Cancer Res (2024) 84 (6_Supplement): 5650.
https://doi.org/10.1158/1538-7445.AM2024-5650
Published: 22 March 2024
View articletitled, Abstract 5650: RNA regulatory disruption by 3’-dATP: A novel approach to inhibit ribosome biogenesis in cancer
Journal Articles

Abstract 6222: Exposing the heterogeneity of the lipidome in the TME of cutaneous melanoma following treatment with NUC-7738 in combination with anti-PD-1 therapy

Free
Alison L. Dickson, Greice M. Zickuhr, In Hwa Um, Ying Zhang, Ruth Plummer, Sarah P. Blagden, Stefan N. Symeonides, Natalie Cook, T.R. Jeffry Evans, Mustafa Elshani, David J. Harrison
Journal: Cancer Research
Cancer Res (2024) 84 (6_Supplement): 6222.
https://doi.org/10.1158/1538-7445.AM2024-6222
Published: 22 March 2024
View articletitled, Abstract 6222: Exposing the heterogeneity of the lipidome in the TME of cutaneous melanoma following treatment with NUC-7738 in combination with anti-PD-1 therapy
Journal Articles

Abstract 5962: NUC-7738 causes reduction of soluble and exosome-associated PD-L1 in melanoma cell lines and patients

Free
Mustafa Elshani, Ying Zhang, Boback Kaghazchi, Alison L. Dickson, Sarah P. Blagden, Stefan Symeonides, Ruth Plummer, David J. Harrison
Journal: Cancer Research
Cancer Res (2023) 83 (7_Supplement): 5962.
https://doi.org/10.1158/1538-7445.AM2023-5962
Published: 04 April 2023
View articletitled, Abstract 5962: NUC-7738 causes reduction of soluble and exosome-associated PD-L1 in melanoma cell lines and patients
Journal Articles

Abstract 931: From bench to bedside: Using ProTide chemistry to transform 3'-deoxyadenosine into the novel anti-cancer agent Nuc-7738

Free
Hagen Schwenzer, Michaela Serpi, Valentina Ferrari, James Chettle, Josephine Morris, Ruud van Stiphout, Erica de Zan, Sebastian Nijman, Mustafa Elshani, Mary Kudsy, David Harrison, Gareth Bond, Sarah P. Blagden
Journal: Cancer Research
Cancer Res (2021) 81 (13_Supplement): 931.
https://doi.org/10.1158/1538-7445.AM2021-931
Published: 01 July 2021
View articletitled, Abstract 931: From bench to bedside: Using ProTide chemistry to transform 3'-deoxyadenosine into the novel anti-cancer agent Nuc-7738
Journal Articles

Germline and Somatic Genetic Variants in the p53 Pathway Interact to Affect Cancer Risk, Progression, and Drug Response

Available to Purchase
Ping Zhang, Isaac Kitchen-Smith, Lingyun Xiong, Giovanni Stracquadanio, Katherine Brown, Philipp H. Richter, Marsha D. Wallace, Elisabeth Bond, Natasha Sahgal, Samantha Moore, Svanhild Nornes, Sarah De Val, Mirvat Surakhy, David Sims, Xuting Wang, Douglas A. Bell, Jorge Zeron-Medina, Yanyan Jiang, Anderson J. Ryan, Joanna L. Selfe, Janet Shipley, Siddhartha Kar, Paul D. Pharoah, Chey Loveday, Rick Jansen, Lukasz F. Grochola, Claire Palles, Andrew Protheroe, Val Millar, Daniel V. Ebner, Meghana Pagadala, Sarah P. Blagden, Timothy S. Maughan, Enric Domingo, Ian Tomlinson, Clare Turnbull, Hannah Carter, Gareth L. Bond
Journal: Cancer Research
Cancer Res (2021) 81 (7): 1667–1680.
https://doi.org/10.1158/0008-5472.CAN-20-0177
Published: 01 April 2021
View articletitled, Germline and Somatic Genetic Variants in the p53 Pathway Interact to Affect Cancer Risk, Progression, and Drug Response
Open the PDF for Germline and Somatic Genetic Variants in the p53 Pathway Interact to Affect Cancer Risk, Progression, and Drug Response in another window
Includes: Supplementary data
Journal Articles

Abstract 1855: NUC-1031 overcomes resistance associated with gemcitabine in cancer patients

Free
Jennifer Bré, Awa Sarr, Peter Mullen, In Hwa Um, Sarah P. Blagden, Paul A. Reynolds, David J. Harrison
Journal: Cancer Research
Cancer Res (2018) 78 (13_Supplement): 1855.
https://doi.org/10.1158/1538-7445.AM2018-1855
Published: 01 July 2018
View articletitled, Abstract 1855: NUC-1031 overcomes resistance associated with gemcitabine in cancer patients
Journal Articles

Abstract B44: Protein interactions involving LARP1 in chemotherapy resistant ovarian cancer cells

Free
Chara Stavraka, Manuela Mura, Roman Fischer, Marie-Laetitia Thezenas, Sadaf Ghaem Maghami, James Chettle, Laki Buluwela, Benedikt Kessler, Sarah P. Blagden
Journal: Cancer Research
Cancer Res (2017) 77 (6_Supplement): B44.
https://doi.org/10.1158/1538-7445.Transcontrol16-B44
Published: 14 March 2017
View articletitled, Abstract B44: Protein interactions involving LARP1 in chemotherapy resistant ovarian cancer cells
Journal Articles

Abstract B30: The RNA-binding protein LARP1 is a cancer therapeutic target

Free
Essam A. Ghazaly, John Le Quesne, Dahai Jiang, Selanere L. Mangala, James Chettle, Cristian Rodriguez-Aguayo, Gabriel Lopez-Berestein, Chathunissa Gnanaranjan, Manuela Mura, Chara Stavraka, Anil K. Sood, Sarah P. Blagden
Journal: Cancer Research
Cancer Res (2017) 77 (6_Supplement): B30.
https://doi.org/10.1158/1538-7445.Transcontrol16-B30
Published: 14 March 2017
View articletitled, Abstract B30: The RNA-binding protein LARP1 is a cancer therapeutic target
Journal Articles

Abstract CT028: First-in-human phase I study of the nucleotide analogue NUC-3373 designed to overcome fluoropyrimidine drug resistance mechanisms

Free
Sarah P. Blagden, Magdalena Slusarczyk, Michaela Serpi, Christopher McGuigan, Essam A. Ghazaly
Journal: Cancer Research
Cancer Res (2016) 76 (14_Supplement): CT028.
https://doi.org/10.1158/1538-7445.AM2016-CT028
Published: 15 July 2016
View articletitled, Abstract CT028: First-in-human phase I study of the nucleotide analogue NUC-3373 designed to overcome fluoropyrimidine drug resistance mechanisms
Journal Articles

Abstract 3390: Validating the RNAscope for molecular profiling of key biomarkers associated with gemcitabine resistance

Free
Essam A. Ghazaly, Chathunissa Gnanaranjan, Bill Greenhalf, Sarah P. Blagden, Peter Mullen, David Harrison, John G. Gribben
Journal: Cancer Research
Cancer Res (2015) 75 (15_Supplement): 3390.
https://doi.org/10.1158/1538-7445.AM2015-3390
Published: 01 August 2015
View articletitled, Abstract 3390: Validating the RNAscope for molecular profiling of key biomarkers associated with gemcitabine resistance
Journal Articles

Polo-like Kinase Plk2 Is an Epigenetic Determinant of Chemosensitivity and Clinical Outcomes in Ovarian Cancer

Free
Nelofer Syed, Helen M. Coley, Jalid Sehouli, Dominique Koensgen, Alexander Mustea, Peter Szlosarek, Iain McNeish, Sarah P. Blagden, Peter Schmid, David P. Lovell, Eleftheria Hatzimichael, Tim Crook
Journal: Cancer Research
Cancer Res (2011) 71 (9): 3317–3327.
https://doi.org/10.1158/0008-5472.CAN-10-2048
Published: 29 April 2011
View articletitled, Polo-like Kinase Plk2 Is an Epigenetic Determinant of Chemosensitivity and Clinical Outcomes in Ovarian Cancer
Open the PDF for Polo-like Kinase Plk2 Is an Epigenetic Determinant of Chemosensitivity and Clinical Outcomes in Ovarian Cancer in another window
Includes: Supplementary data